Analysis shows benefits of NeuroStar TMS for Depression-Neuronetics

Neuronetics has announced a new analysis that shows Transcranial Magnetic Stimulation (TMS) administered with the NeuroStar TMS Therapy System resulted in greater symptom improvement than next-choice conventional antidepressant medication among patients with Major Depressive Disorder (MDD) who failed to benefit from prior antidepressant medication. In a propensity-score matched analysis of data from two independent studies, patient-reported symptom outcomes measured by the Quick Inventory of Depressive Symptomatology-Self Report (QIDS-SR), showed that after 6 weeks of acute phase treatment, 53 percent of patients treated with NeuroStar TMS Therapy reported no or mild depression.

In contrast, the propensity-score matched population of patients treated with next-choice antidepressant medication showed improvement among 38 percent of patients (P<0.0001 for the contrast between the two groups, favoring neurostar tms therapy). a companion study also presented found that neurostar tms therapy is cost-effective for patients who fail to benefit from prior antidepressant medication, with mean annual costs of $11,886 and $10,888 for tms and star*d patients, respectively. data were presented at the annual meeting of the american psychiatric association.>